It’s looking like chances that the holiday season would be different from last year are fading. Though booster vaccinations are still seen as a bulwark against serious illness from the latest mutation of the coronavirus, fears of an unprecedented wave continue to grow along with the global rate of infection, which now matches the height of the summer delta wave. The U.K., which has been overwhelmed by the new omicron strain, is seen as a harbinger of things to come everywhere else. On Thursday, France said it will ban tourists and almost all business travelers from Britain in a bid to slow the spread. The plan comes after the U.K. recorded its highest number of new cases since the beginning of the crisis. Here’s the latest on the pandemic. —David E. Rovella
Thursday, December 16, 2021
Friday, March 12, 2021
Global Big Pharma Partnering Deals, Terms and Agreements Directory 2021: Comprehensive Listing of the Top 50 Companies Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson
Global Big Pharma Partnering Deals, Terms and Agreements Directory 2021: Comprehensive Listing of the Top 50 Companies Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson
The "Global Big Pharma Partnering Terms and Agreements 2014-2021" report has been added to ResearchAndMarkets.com's offering.
The Global Big Pharma Partnering Terms and Agreements 2014-2021 report provides comprehensive access to available deals and contract documents for over 3,400 Big Pharma deals.
Global Big Pharma Partnering Terms and Agreements 2014 to 2021 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Big Pharma agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.
The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Big Pharma deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announced by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.
Analyzing actual contract agreements allows assessment of the following:
-- What are the precise rights granted or optioned?
-- What is actually granted by the agreement to the partner company?
-- What exclusivity is granted?
-- What is the payment structure for the deal?
-- How are sales and payments audited?
-- What is the deal term?
-- How are the key terms of the agreement defined?
-- How are IPRs handled and owned?
-- Who is responsible for commercialization?
-- Who is responsible for development, supply, and manufacture?
-- How is confidentiality and publication managed?
-- How are disputes to be resolved?
-- Under what conditions can the deal be terminated?
-- What happens when there is a change of ownership?
-- What sublicensing and subcontracting provisions have been agreed?
-- Which boilerplate clauses does the company insist upon?
-- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
-- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Big Pharma dealmaking
2.1. Introduction
2.2. Big Pharma partnering over the years
2.3. Most active Big Pharma dealmakers
2.4. Big Pharma partnering by deal type
2.5. Big Pharma partnering by therapy area
2.6. Big Pharma partnering by technology type
2.7. Deal terms for Big Pharma partnering
Chapter 3 - Leading Big Pharma deals
3.1. Introduction
3.2. Top Big Pharma deals by value
Chapter 4 - Most active Big Pharma dealmakers
4.1. Introduction
4.2. Most active Big Pharma dealmakers
4.3. Most active Big Pharma partnering company profiles
Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others
Chapter 5 - Big Pharma contracts dealmaking directory
5.1. Introduction
5.2. Big Pharma contracts dealmaking directory
Chapter 6 - Big Pharma dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - Big Pharma deals by company A-Z
Appendix 2 - Big Pharma deals by stage of development
Appendix 3 - Big Pharma deals by deal type
Appendix 4 - Big Pharma deals by therapy area
Appendix 5 - Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/jfevbk
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
 | CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
| |
https://ml.globenewswire.com/media/908fb457-7f8e-4a08-9081-5565e3dfb3d7/small/22157-jpg.jpg
analysts comments
several week
stabilization
day of point
jan 17 down %
march 8 %
the stimulus is working
valuable continue to work
this morning big swing there
if you want to take a look
S&P take a look
GMC
12 march 3:03 am
ogen remain at 1.07
HTBX DOWN TO 9.15 TO 8.65 (to buy again in morning)
BIOL down more 0.9081 at 3:03 am 12 march 2021 closing at 0.93xx (net loss 380 )
TD 10826.93 (380.71 down premarket as of 3:23 ( 12 mar 2021)
ogen gain -3.16
txmd -15.76
biol -126.10
txnp 59.28 (65)
ctrm -15.43
cidm-41.08
gern-7.85
pfe
TXMD DOWN MORE 1.56 DOWN TO 1.47 MY AVG IS 1.64-
Friday, March 5, 2021
UPDATE: Dow slides 460 points, Nasdaq sees correction after Powell
Stock Futures Slip Ahead of Jobs Data
Stock Futures Slip Ahead of Jobs Data
U.S. stock futures dropped at the end of a downbeat week for major indexes and ahead of a monthly update on the job market.
Futures on the S&P 500 slipped 0.4% and Dow Jones Industrial Average futures declined 0.4%. The contracts don't necessarily predict market moves after the markets open.
Europe stocks fell Friday for a two-day losing streak. The Stoxx Europe 600 lost 0.8% in morning trade dragged down by declines in communication services and information technology sectors.
The U.K.'s FTSE 100, which is dominated by large international businesses, shed 0.8%. Other stock indexes in Europe also mostly fell as France's CAC 40 was down 0.9%, the U.K.'s FTSE 250 fell 0.6% and Germany's DAX shed 0.8%.
The Swiss franc, the euro and the British pound slipped 0.2%, 0.3% and 0.3% respectively against the U.S. dollar.
In commodities, international benchmark Brent crude strengthened 1.4% to $67.66 a barrel. Gold was down 0.6% to $1,690.60 a troy ounce.
German 10-year bund yields rose to minus 0.303% and the yield on U.K. 10-year gilts gained to 0.753%. The 10-year U.S. Treasury yield ticked up to 1.551% from 1.547%. Bond yields move inversely to prices.
In Asia, indexes mostly fell as Hong Kong's Hang Seng was mostly flat, losing 0.1%, Japan's Nikkei 225 index was lower 0.2%, and China's benchmark Shanghai Composite was broadly flat between minus 1% and 0.6%.
An
artificial-intelligence tool
was used in creating this article.
2021-03-05 09:54:00 GMT DJ S&P 500 on Track for Third Week of Declines, Led by Tech
By Joe Wallace
U.S. stock futures fell Friday, pointing to another day of losses for major indexes as investors awaited the monthly jobs report for fresh insights into the health of the labor market.
Futures linked to the S&P 500 edged down 0.4%. The S&P 500 is on track for its third week of declines. It was down 1.1% for the week by the end of Thursday, and closed at its lowest level since the end of January.
Contracts tied to the technology-heavy Nasdaq-100 fell 0.6%, suggesting that the sector will continue to lead the retreat after the opening bell.
Stocks have stumbled in recent weeks as a climb in bond yields has called into question whether low interest rates, which propelled valuations higher for much of the past year, can continue for much longer. Yields, which rise as bond prices fall, have rallied in response to expectations of a quickening pace of growth and inflation as the economy reopens from the coronavirus pandemic.
The yield on 10-year Treasury notes ticked up again Friday, to 1.557%, from 1.547% Thursday. That marked the highest level for the benchmark borrowing cost since February last year. The latest climb in yields came after Federal Reserve Chairman Jerome Powell provided no sign the central bank would seek to stem the rise when he spoke at The Wall Street Journal Jobs Summit.
"It is all about the bond-yield moves. It is all about Jerome Powell," said Edward Park, chief investment officer at Brooks Macdonald. "There is a huge amount of uncertainty in the market at the moment as to whether the inflation that is widely expected in the short term. is transient or whether it is more sustained."
Bond yields are likely to keep rising and stocks may remain jittery unless the Fed takes concrete steps to put a cap on yields, according to Mr. Park. "Markets are at their most volatile when they are not sure how monetary policy and fiscal policy is going to react."
Technology stocks have borne the brunt of the shift in sentiment in recent weeks. The Nasdaq Composite Index, a closely watched barometer for the sector, on Thursday fell to its lowest level since Jan. 4. The index ended the day down 9.7% from its Feb. 12 high, putting it just short of correction territory.
Investors will later parse the February jobs report, due to be released at 8:30 a.m. ET. It is expected to show that the economy created 210,000 jobs last month. That would add to signs of a slow improvement in the labor market, after data on Thursday showed filings for unemployment benefits reached their lowest level in three months.
The jobs report may not sway bond yields much because the data are unlikely to affect the progress of the Biden administration's stimulus package through the Senate, said Lyn Graham-Taylor, senior rates strategist at Rabobank. The Senate on Thursday advanced the $1.9 trillion bill after making a series of adjustments, and is expected to give its approval within days.
Yields are likely to keep heading higher, according to Mr. Graham-Taylor. "So far the Fed's emphasized that it's not loving it, but it is pretty comfortable with it," he said. "In the back of their minds, it is natural for yields to rise a bit: We're not in the eye of the storm as we were."
Oil prices rallied for a second day after OPEC and a Russia-led coalition of oil producers kept most of their production cuts in place, taking the market by surprise. Brent crude, the benchmark in international energy markets, rose 1.9% to $68.02 a barrel.
Overseas, the pan-continental Stoxx Europe 600 ticked down 0.5%.
Major Asian indexes ended the day down. Japan's Nikkei 225 ticked 0.2% lower, while Hong Kong's Hang Seng Index dropped almost 0.5%.
Write to Joe Wallace at Joe.Wallace@wsj.com
(END) Dow Jones Newswires
March 05, 2021 04:54 ET (09:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
News Highlights: Top Energy News of the Day
Today 4:00 AM ET (Dow Jones)Print Norsk Hydro Sells Rolling Unit in $1.7 Billion Deal Norway's Norsk Hydro has agreed to sell its rolled-products business to U.S. private-equity firm KPS Capital Partners in a deal worth $1.66 billion. U.S. oil prices log highest finish since 2019 as OPEC+ agrees to extend production curbs Oil futures rally Thursday, with U.S. prices posting their highest finish since 2019 after the Organization of the Petroleum Exporting Countries and its allies said they will rollover current production cuts to the end of April. OPEC-Plus Keeps Lid on Oil Output, and Prices Rise OPEC and a Russia-led coalition of oil producers kept most of their production cuts in place, surprising traders and sending oil prices up dramatically. Texas Overcharged $16 Billion for Power During Freeze The state extended peak prices for more than a day longer than needed, said the independent monitor, which is recommending the charges be reversed. Judge Allows Challengers to Trump-Era Oil Drilling Safety Rule to Review Agency Records A federal judge in Louisiana says an oil-safety regulator must turn over communications as part of a lawsuit over a Trump administration change. Winter Storm Eased Natural-Gas Glut Though the climb in gas prices was short lived, producers and analysts say that enough gas was burned during the cold snap to likely keep prices from crashing when furnaces are shut off in spring. Wind Power Was Thriving in Texas. Then Came the Freeze. Wind farms have boomed in the Lone Star State, but one week of extreme wholesale power prices left many operators in financial distress. Texas Power Grid Operator Fires CEO The board of the Texas electric-grid operator fired Chief Executive Bill Magness, less than a month after the state's power grid came within minutes of collapse. Energy & Utilities Roundup: Market Talk The latest Market Talks covering Energy and Utilities Texas Power Regulator Urged to Halt Collections as Crisis Fallout Spreads Electricity retailers are asking Texas' power regulator to suspend immediate collections on the massive bills arising from the state's electricity outage, as energy market participants try to mitigate the threat to their financial health. (END) Dow Jones Newswires March 05, 2021 04:00 ET (09:00 GMT) Copyright (c) 2021 Dow Jones & Company, Inc. |
, 
, 
, 
Copyright ©2021. All rights reserved.CFRA Research Disclosure /wwws-4:58:35
3rd Party Research Disclosure /wwws-4:58:35
Sunday, December 6, 2020
correction to Data Week Ahead on Dec. 4
correction to Data Week Ahead on Dec. 4
The University of Michigan preliminary consumer survey (Consumer Sentiment) will be released Friday, Dec. 11. "Consumer Price Index and Producer Price Index on Tap -- Data Week Ahead" published on Dec. 4 at 2:14 p.m. ET incorrectly labeled the event as Consumer Price Index.
(END) Dow Jones Newswires
December 05, 2020 11:17 ET (16:17 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Wednesday, December 2, 2020
3 ETFs for the reopening trade
Some of the most talked-about investing bets of the past year aren’t the companies that benefited from the COVID-19 lockdowns or business activity going virtual. Rather, they’re the ones whose stocks stand to pop when it’s all over.
Think of the U.S. Global Jets ETF JETS, +0.75%, which has soared to a whopping $2.6 billion in assets, even as it weathers a bumpy ride, pardon the pun, as market sentiment toggles between optimism and gloom about the reopening of the economy and the resumption of normal life.
In the spirit of fresh starts, MarketWatch asked an expert on exchange-traded funds for some reopening recommendations that aren’t quite as concentrated as JETS, and are likely to survive, even thrive, in what’s likely to be a turbulent period through the worst of the winter and into a world where coronavirus treatments are readily available.
One of the best bets for any investor might be the Invesco Dynamic Leisure and Entertainment ETF PEJ, -0.17%, which owns exactly what you think it might, based on the name, noted Todd Rosenbluth, head of mutual fund and ETF research for CFRA, but in a much more approachable portfolio than the pure-play JETS.
PEJ’s holdings include companies and industries that have been smacked hard by the pandemic, like hotels, casinos, and Walt Disney Co. DIS, +2.05%
“Even as vaccines are rolled out, certain parts of the consumer experience will improve at different rates: people might be more inclined to go to restaurants, to maybe take a trip by car, but maybe not by plane,” Rosenbluth said. “There won’t be a straight line up in terms of consumer spending so the diversification of this fund will help.”
PEJ doesn’t just diversify in terms of business models. It also has a mixture of large, mid, and small cap stocks, as well as growth and value companies, Rosenbluth noted. A portfolio with exposure to small-caps and value stocks should benefit from greater economic improvement and cyclicality.
Another selection, the SoFi 50 SFYF, +0.36%, is unique among ETFs: it includes stocks from companies where SoFi platform members have invested the most money. Because it’s rebalanced monthly to take advantage of that fluid situation, rather than quarterly, like many ETFs, this fund may respond more quickly to changes in consumer habits and regulations.
“If investors are becoming more bullish on the reopening and owning more travel and leisure and restaurants and other cyclical companies, then that’s what this ETF will have exposure to,” Rosenbluth said in an interview. “It may be a lagging indicator, but it’s more aligned with certain investor sentiment.”
As of the end of November, the fund’s portfolio included a healthy dose of hunker-down plays, like Amazon.com Inc. AMZN, -0.14%, Zoom Video Communications ZM, +1.42%, and Shopify Inc. SHOP, +0.91%, as well as several reopening names, like Delta Air Lines Inc. DAL, +2.34% and Carnival Corp., CCL, +3.54% among its top holdings. It’s also up 30% in the year to date, a sign its crowd-sourced methodology hasn’t done so badly.
Finally, if you’re most bullish on the travel sector, but want a bit more diversification than JETS offers, take a look at the ETFMG Travel Tech ETF, AWAY, +2.51% which launched in late February.
“You could not have dreamed up an ETF that was more poorly positioned for the shutdown that’s now eight months old,” Rosenbluth said. “That said, it’s recovered nicely.”
AWAY has just about broken even in the year to date, but is up a whopping 43% so far in November, suggesting lots of investors see value in its holdings.
As fits its name, AWAY invests in companies that provide infrastructure for the travel industry, like booking companies Sabre Corp. SABR, +3.60% and MakeMyTrip Ltd. MMYT, +0.52% It’s diverse in terms of country exposure, which may be a plus if different countries and regions start to open up to travel at different times.
More On MarketWatch
About the Author
Andrea Riquier reports on housing and banking from MarketWatch's New York newsroom. Follow her on Twitter @ARiquier.
Saturday, November 28, 2020
Frontline's CEO Robert Macleod on Q3 2020 Results -- Earnings Call Transcript >FRO Today 4:30 AM ET (Dow Jones)Print
Frontline's CEO Robert Macleod on Q3 2020 Results -- Earnings Call Transcript >FRO
From Seeking Alpha:
(END) Dow Jones Newswires
November 28, 2020 04:30 ET (09:30 GMT)
Aviva plc CEO Amanda Blanc on Q3 2020 Results -- Earnings Call Transcript >AIVAF
Aviva plc CEO Amanda Blanc on Q3 2020 Results -- Earnings Call Transcript >AIVAF
From Seeking Alpha: Aviva plc CEO Amanda Blanc on Q3 2020 Results -- Earnings Call Transcript https://seekingalpha.com/article/4391720-aviva-plc-aivaf-ceo-amanda-blanc-on-q3-2020-results-earnings-call-transcript?utm_source=dowjonesnewswire.com&utm_medium=referral
(END) Dow Jones Newswires
BRP, Inc. CEO José Boisjoli on Q3 2021 Results -- Earnings Call Transcript >DOOO
BRP, Inc. CEO José Boisjoli on Q3 2021 Results -- Earnings Call Transcript >DOOO
From Seeking Alpha:
(END) Dow Jones Newswires
November 28, 2020 04:30 ET (09:30 GMT)
Model Katiana Kay Launches Bay Smokes
Model Katiana Kay Launches Bay Smokes
Katiana Kay had numerous reasons for starting up her business Bay Smokes. The legal cannabis and auxiliary industries are growing not only in the United States, but also in other countries that have taken a softer stance on the popular plant. Thanks to this newly found openness, it's possible to have a whole new kind of hemp product consumers can't just call marijuana, even if they wouldn't be too off the mark if they did.
Bay Smokes is a line of smokable hemp products released by Katiana Kay. Unlike other products, it manages to walk the fine line between being a novelty and providing a genuine alternative to people who like their plant material smoked.
Entering the Market
Because of how much the market has grown, finding a way in that's both fresh and interesting on one side and potentially lucrative on the other side was the first task Katiana had to master before launching her product line. Thankfully for her, she had a keen eye for spotting opportunities when they presented themselves, even for a second.
Katiana understood the issue many people who enjoy THC-heavy products experience; it's not exactly the most productive of things to consume. There are other side effects that come from using them, too, such as anxiety and paranoia. For many, it's not a happy place to inhabit, so Katiana decided to offer something recognizable but slightly different.
She entered the market with her brand of smokable hemp products called Bay Smokes and quickly found her bearings and an audience willing to try what she has to offer. From people looking to quit tobacco to people opting for a milder experience with hemp, Bay Smokes was made to make them happy.
Looking Further into the Future
One thing no one could accuse Katiana of is staying still for too long. Right now, this entrepreneurial lady has a couple of steps planned out to make sure that everyone who needs to know about Bay Smokes gets their info. For now, the idea is to rely on social media for marketing and promotion and to focus on building a sales platform that can help farmers who produce the best possible products break into the market.
This venture, however, is only one half of what Katiana has going on for her. She uses her other venture to fund this one and has plans in the works to use the profits from both to fund something completely new. One thing's for sure: it will probably revolve around helping people.
| Katiana Kay Owner of Bay Smokes @baysmokeshemp Baysmokes.com | |
- 1.the quality of being new, original, or unusual.
- depend on with full trust or confidence."I know I can rely on your discretion"
- be dependent on."the charity has to rely entirely on public donations"